Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.43 USD | -0.41% | -3.50% | -88.04% |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Apr. 02 | JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 72.78M |
---|---|---|---|---|---|
Net income 2024 * | -81M | Net income 2025 * | -94M | EV / Sales 2024 * | - |
Net cash position 2024 * | 51.8M | Net cash position 2025 * | 82.3M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.95
x | P/E ratio 2025 * |
-1.04
x | Employees | 41 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.11% |
1 day | -0.41% | ||
1 week | -3.50% | ||
Current month | +2.12% | ||
1 month | -19.64% | ||
3 months | -87.75% | ||
6 months | -84.08% | ||
Current year | -88.04% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 17-01-31 | |
Eric Easom
FOU | Founder | 56 | 17-01-31 |
Lucy Day
DFI | Director of Finance/CFO | 65 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 60 | 17-01-31 | |
Patricia Martin
BRD | Director/Board Member | 63 | 21-03-31 |
Melvin Spigelman
BRD | Director/Board Member | 75 | 22-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 0 M€ | +8.23% | - | |
0.00% | 0 M€ | +3.15% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 2.451 | +0.45% | 14 613 |
24-05-08 | 2.44 | -4.31% | 74,564 |
24-05-07 | 2.55 | -1.54% | 91,221 |
24-05-06 | 2.59 | +1.17% | 127,992 |
24-05-03 | 2.56 | +0.79% | 168,385 |
Delayed Quote Nasdaq, May 09, 2024 at 10:32 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.04% | 72.78M | |
+24.98% | 46.71B | |
+48.83% | 41.8B | |
-1.19% | 41.52B | |
-3.42% | 29.55B | |
+10.22% | 25.78B | |
-20.54% | 19.26B | |
+0.67% | 12.14B | |
-0.28% | 12.08B | |
+26.07% | 11.98B |
- Stock Market
- Equities
- ANTX Stock